Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6426277 | 0.95 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2LMNAMAPK1GAA | |
| SCHEMBL6426948 | 0.87 | L3MBTL1 (0.37) | ALDH1A1LMNAGAAMAPTMEN1 | |
| SCHEMBL6387641 | 0.86 | XIAP (0.36) | MEN1KMT2A | |
| SCHEMBL6427696 | 0.84 | DPP8 (0.34) | ALDH1A1GAATSHRKDM4E | |
| SCHEMBL6427323 | 0.83 | DPP4 (0.40) | ALDH1A1LMNAKDM4EPKMMAPT | |
| SCHEMBL6426470 | 0.83 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2LMNAMAPK1GAA | |
| SCHEMBL6427585 | 0.82 | ALDH1A1 (0.43) | ALDH1A1GAAKDM4EMEN1KMT2A | |
| SCHEMBL6506436 | 0.82 | TSHR (0.53) | ALDH1A1SMN1; SMN2MAPK1GAAGRM7 | |
| SCHEMBL6502545 | 0.82 | TSHR (0.53) | ALDH1A1SMN1; SMN2MAPK1GAAGRM7 | |
| SCHEMBL6500660 | 0.82 | TSHR (0.53) | ALDH1A1SMN1; SMN2MAPK1GAAGRM7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | claimed |
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239853-A1 | New compounds | HSD11B1, CYP11B1, HSD3B1 | ALDH1A1 67/4885SMN1; SMN2 3733/4885LMNA 1964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.